UNITE Study (UMN-GE) for COVID-19

Sponsor

University of Minnesota (Other)

Overall Status

Completed

CT.gov ID

NCT04701489

Collaborator

General Electric Research (Industry), DARPA (Department of Defense) (Other)

Enrollment

Location

Arms

2.7

Actual Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The research objective of the UNITE Study is to assess the potential efficacy of ultrasound application to the spleen in the treatment of coronavirus disease 2019 (COVID-19) in a pilot study.

Specific Aims:

Determine the efficacy of splenic ultrasound in affecting markers of systemic inflammation in COVID-19 infection.
Evaluate the potential efficacy of splenic ultrasound in affecting clinical outcomes in COVID-19 infection.

Condition or Disease	Intervention/Treatment	Phase
Covid19 Cytokine Storm Inflammation	Device: Splenic ultrasound	N/A

Detailed Description

Ultrasound is widely used in human medicine because it is safe, non-invasive, and painless. The same kind of ultrasound that is used for imaging (for example, to visualize babies in utero) may be able to treat inflammatory diseases including COVID-19. COVID-19 is a disease caused by infection with the SARS-CoV-2 virus. Some COVID-19 patients develop a severe respiratory disease called acute respiratory distress syndrome and this disease is caused, in part, by a significant increase in inflammatory factors. Clinical therapies that reduce this elevated inflammation in the body (e.g., inflammation molecules in your body called cytokines) may be capable of diminishing symptoms in severe cases of COVID-19.

Multiple studies in animals with hyper-inflammation conditions (e.g., inflammatory arthritis and sepsis/LPS injections) and recent human studies (e.g., for the treatment of joint inflammation in Rheumatoid Arthritis) have shown that ultrasound applied to the spleen can suppress blood/genetic markers of inflammation. Similar inflammatory markers, or cytokines, are elevated in the lungs of COVID-19 patients and believed to cause severe symptoms. Splenic ultrasound can potentially lower these inflammatory cytokines without hindering antibody production, leading to clinical improvements in COVID-19 patients.

This study will employ ultrasound devices produced by General Electric (GE LOGIQ E10 device with C1-6 ultrasound probe) that are currently used in hospitals and approved for diagnostic imaging by the FDA. The ultrasound energies applied to the spleen in this study in COVID-19 patients will not exceed what is currently approved for diagnostic imaging with those GE ultrasound devices.

There will be two groups in this study with 15 participants in each group. One group will receive ultrasound application to the spleen, in addition to the standard clinical care. A control group will receive standard clinical care without splenic ultrasound. Each ultrasound application session will last about 15-20 minutes per day for 7 days, unless the participant is discharged sooner. For ultrasound stimulation, a small gel-coated probe is positioned on the upper left abdomen area over the ribs. The ultrasound session includes a period of 5-10 minutes when study personnel use the ultrasound device to locate the spleen and to position the ultrasound probe in a proper location around the ribs area, and an approximately 10-minute period for application of ultrasound to the spleen. Collection of clinical outcome data and daily blood draws will be performed in each participant throughout the study. Additional data collected from each participant during their routine clinical care beyond their study involvement will also be analyzed together with the study data to evaluate the specific aims of the clinical trial.

Study Design

Study Type:

Interventional

Actual Enrollment :

30 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

The participants will be randomized to two groups: ultrasound group and control group. All participants will still receive standard clinical care. The ultrasound group will receive daily ultrasound application to the spleen for up to 7 days, in addition to the standard clinical care. The control group will receive standard clinical care without ultrasound stimulation.The participants will be randomized to two groups: ultrasound group and control group. All participants will still receive standard clinical care. The ultrasound group will receive daily ultrasound application to the spleen for up to 7 days, in addition to the standard clinical care. The control group will receive standard clinical care without ultrasound stimulation.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Ultrasound Neural and Immunomodulation Treatment Evaluation Study (UMN-GE) for COVID-19

Actual Study Start Date :

Jan 14, 2021

Actual Primary Completion Date :

Mar 15, 2021

Actual Study Completion Date :

Apr 7, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Ultrasound Group Daily ultrasound application to the spleen of approximately 10 minutes for up to 7 days, in addition to standard clinical care.	Device: Splenic ultrasound GE LOGIQ E10 device with C1-6 ultrasound probe
No Intervention: Control Group Standard clinical care with no ultrasound stimulation.

Arm

Intervention/Treatment

Experimental: Ultrasound Group

Daily ultrasound application to the spleen of approximately 10 minutes for up to 7 days, in addition to standard clinical care.

Device: Splenic ultrasound

GE LOGIQ E10 device with C1-6 ultrasound probe

No Intervention: Control Group

Standard clinical care with no ultrasound stimulation.

Outcome Measures

Primary Outcome Measures

Between-arm change of IL-6 levels from baseline to end of treatment between groups [Baseline to Day 8 (end of treatment; or date of discharge)]
Between-arm change of IL-1β levels from baseline to end of treatment between groups [Baseline to Day 8 (end of treatment; or date of discharge)]
Between-arm change of CRP levels from baseline to end of treatment between groups [Baseline to Day 8 (end of treatment; or date of discharge)]

Secondary Outcome Measures

Change in time to recovery [Baseline to date of recovery, assessed up to 21 days]
Day of recovery is defined as the first day on which the subject satisfies this category from the ordinal scale: Hospitalized, no oxygen therapy

Other Outcome Measures

Change in death rate [Baseline to date of discharge or date of death, whichever came first, assessed up to 6 months]
Change in rate of requiring mechanical ventilation [Baseline to date of discharge or date of death, whichever came first, assessed up to 6 months]
Change in duration of hypoxemia [Baseline to date of discharge or date of death, whichever came first, assessed up to 6 months]
Change in D-dimer levels [Baseline to Day 8 (end of treatment; or date of discharge)]
Change in serum cytokine concentration of TNF [Baseline to Day 8 (end of treatment; or date of discharge)]
Change in serum cytokine concentration of IL-10 [Baseline to Day 8 (end of treatment; or date of discharge)]
Change in serum cytokine concentration of IFN-gamma [Baseline to Day 8 (end of treatment; or date of discharge)]
Change in serum cytokine concentration of IL-18 [Baseline to Day 8 (end of treatment; or date of discharge)]
Change in serum cytokine concentration of IL2R-alpha [Baseline to Day 8 (end of treatment; or date of discharge)]
Change in serum cytokine concentration of IL-4 [Baseline to Day 8 (end of treatment; or date of discharge)]
Change in RNAseq identified pro-inflammatory pathways [Baseline to Day 8 (end of treatment; or date of discharge)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age 18 and above
Positive for SARS-CoV-2 (via PCR)
Decreased blood oxygen saturation: Room air SaO2 < 94% and/or requiring supplemental oxygen to maintain SaO2 > 90%
Admission to the hospital

Exclusion Criteria:

Pregnant women
Asplenia
Ascites
Open wound/sores near the stimulation site
Recent abdominal surgery
Splenomegaly
Mechanically ventilated (if patient goes onto mechanical ventilation while participating in the study, they can continue ultrasound treatment if recommended by standard of care clinician and investigators of the study)
Comfort care status
Any other clinical reasons deemed by the investigators of the study in which the patient would not be an appropriate candidate for the study